Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

5 treatments under study, led by Bi 1701963

Research Leaders

9 sponsors active, led by Sahlgrenska University Hospital

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 77/100

Termination Rate

50.0%

2 terminated out of 4 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results50% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
Phase 1 (1)
Phase 3 (1)

Trial Status

Terminated2
Completed2

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT04534075Phase 3Completed

Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial

NCT04964297Not ApplicableTerminated

Evaluation of Ability to Detect Bowel Gas During Laparoscopic Right Colectomy With Intracorporeal Anastomosis

NCT04975256Phase 1Terminated

Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

NCT02378337Completed

Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality

Showing all 4 trials

Research Network

Common Treatments

  • Bi 17019631
  • Adagrasib1
  • Capsules Containing Either Dietary Fiber Or Placebo1
  • Image Quantify1
  • Obtaining Bowel Gas Samples1

Active Sponsors

  • Sahlgrenska University Hospital1
  • Mirati Therapeutics Inc.1
  • Sentire Medical Systems1
  • Boehringer Ingelheim1
  • Hospital Sao Rafael1

Top Investigators

Related Conditions

  • Gynecologic Cancer1
  • Malignant Neoplasm Of Rectum1
  • Malignant Neoplasm Of Small Intestine1
  • Metastatic Cancer1
  • Malignant Neoplasm Of Lung1

Activity Timeline